Tuesday, March 09, 2021 9:37:43 AM
Yep this ironical article illustrates exactly the central defect in Cytodyn's paper that makes every data manipulated:
the complete lack of control for multiplicity for all the post-hoc tests. They apparently went on a fishing expedition, performing multiple tests on anything that could matter until they found the best possible magical combination (split by age at 65 years old precisely, no more no less, then split following the other treatments, and only some of them precisely handpicked). And of course they never discuss correction of the p-values obtained from that multiplicity of tests. Which is, statistically, completely illlegal and makes p-values completely fake.
We are not talking here about minor corrections: to make it correct again, we may need to multiply Cytodyn p-values by x30, x50 or more (we don't know how many tests they performed in their fishing expedition) to correct for this data mining. The resulting p-values are so irrelevant that it proves that Cytodyn has been just overfitting noise. It's a giant lotto game, they have thrown dozens or maybe hundreds of balls (the tests performed), who knows, and then, have handpicked only the balls that served their storyline. And have conveniently dissimulated the key statistics about the other balls from shareholders.
the complete lack of control for multiplicity for all the post-hoc tests. They apparently went on a fishing expedition, performing multiple tests on anything that could matter until they found the best possible magical combination (split by age at 65 years old precisely, no more no less, then split following the other treatments, and only some of them precisely handpicked). And of course they never discuss correction of the p-values obtained from that multiplicity of tests. Which is, statistically, completely illlegal and makes p-values completely fake.
We are not talking here about minor corrections: to make it correct again, we may need to multiply Cytodyn p-values by x30, x50 or more (we don't know how many tests they performed in their fishing expedition) to correct for this data mining. The resulting p-values are so irrelevant that it proves that Cytodyn has been just overfitting noise. It's a giant lotto game, they have thrown dozens or maybe hundreds of balls (the tests performed), who knows, and then, have handpicked only the balls that served their storyline. And have conveniently dissimulated the key statistics about the other balls from shareholders.
Recent CYDY News
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
